|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0048 - 0.0048|
|52 Week Range||0.0001 - 0.0090|
|Beta (5Y Monthly)||165.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.
A single dose of either the AstraZeneca–Oxford vaccine or the Pfizer–BioNTech COVID-19 shot cuts the risk of hospital admission among older adults by more than 80% percent, Public Health England (PHE) said, citing a preprint study. The real world study, which was published on Monday and hasn’t yet been peer-reviewed, showed that protection against any COVID-19 symptoms in those over 70 ranged between 57% and 61% for one dose of the Pfizer–BioNTech shot, and between 60% and 73% for the AstraZeneca–Oxford one four weeks after the first shot.
Distribution began Monday for Johnson & Johnson's newly authorized one-shot coronavirus vaccine, leading JNJ stock to pop in early action. McKesson is distributing the J&J vaccine.